about
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.A new automated method for continuous registration of factor VII activation in vitro. Activation is accelerated by the concentration of factor VII and the activity state of the protein.Diet and blood coagulation factor VII--a key protein in arterial thrombosis.A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel.The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.Mean transit times and the sites of synthesis and catabolism of tissue plasminogen activator and plasminogen activator inhibitor type 1 in young subjects.Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor.Inflammation, thrombosis and atherosclerosis: results of the Glostrup study.Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal.International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain.Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution.Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D.The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate.Factor VII-activating protease in patients with acute deep venous thrombosis.Postprandial coagulation activation in overweight individuals after weight loss: acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet.Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics.Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS).Gender Differences in Fibrin Polymerization and Lysability of Fibrin in Patients with Atrial Fibrillation.Effects on markers of inflammation and endothelial cell function of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals.Long-term effects on haemostatic variables of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals.A high-fat meal does not activate blood coagulation factor VII in minipigs.Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives.Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently.Association of factor VII protein concentration with lifestyle factors.Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men.Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet.Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.Warfarin or dabigatran for treatment of atrial fibrillation.External quality assessment (EQA) for CoaguChek monitors.Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity.Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapyGenetic Influence on Inflammation Variables in the ElderlyEffect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled studyNon-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelDistinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgeryThe use of evacuated glass tubes for collection of blood samples for fibrinolytic assaysThe assay of factor Xa on a centrifugal analyzerEffects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young womenA comparison of the effects of cimetidine and epsilon-aminocaproic acid on fibrinolysis induced by activators of plasminogen and on fibrin formationInfluence of plasma platelets on activated protein C resistance assay
P50
Q31129827-78583AAD-4E35-4A7C-9999-294443914D17Q41013958-CBD0708A-12D3-437E-842B-7F77E37C0C4CQ41722179-D81997D7-7AB4-4B0D-A5DE-495EEB5466BFQ42662488-261C2783-FE92-454D-877F-0C484E5B6B6BQ42714228-54872176-F6BA-4C9E-BED5-CD954DBEF29BQ43816508-E88DC635-C646-418C-A388-E7E40553EE5EQ44232645-23C2AEB3-E934-4428-99EA-79BFD9E4D46EQ44518799-155945E0-26B9-4474-9DDA-B7F152BFBFE0Q44773326-038751A1-EEF6-47DD-A881-3892A244F2D5Q45873540-552692D9-DC5D-4CE3-8A8E-068962A495B4Q45878722-7DA3D905-88AD-4807-A47E-3886C3D58C55Q46290245-41F80D08-4A9B-4E8C-A2B0-9D4690609C11Q46621922-8A9D462B-95D6-498D-86B6-4EE91D681A2AQ46659852-554C0E06-DD41-4FC0-B596-E92E8F99A719Q47192690-98B4EB91-5B3A-4122-8D04-AC9E137F90DCQ50233503-4997D205-F363-42A7-83F3-648F0345E7BEQ50543668-4FDBCB50-85C1-47CB-B102-2380291FFCFDQ50964356-A3A329B9-DD36-41C3-8A2A-197161EA48E6Q51379285-13451142-3EE6-4B74-8664-E69351B54D06Q51394056-DE6A8572-85EC-49C4-93FA-40C6A4E845F2Q51549706-85968A6B-86A9-4F5C-8DE0-939667A0903EQ51557700-1AE25FCA-B8E5-4762-A73B-54BEF3DB0B4AQ51559625-1EC80D04-9A49-4F47-BBC9-684EF3D9B1CDQ51567999-444EEBEA-9C3C-4424-A547-ABA681EAE08DQ51572143-20E12E8D-0E2B-46E9-A299-2073008208EAQ51595192-D91EE8DD-885A-42D0-98C8-A79B11D980D0Q52733637-5CD9C9DD-C701-4CD0-985A-ECB8E77F7361Q53090842-B4B8BFE6-009B-4E38-8676-4ECABB47664EQ53177505-2CB41E6C-7629-41C3-B6ED-293610CEF8CDQ53387578-EF67C21A-B5EB-4A54-AEFB-609E6BEFD17DQ58301440-F4EE48D5-BA4A-484C-9A1A-B3830BB8448AQ58301528-707F0C31-E07A-408A-AD02-49A284B70D10Q59057086-1FDEDA0D-9662-4A49-B52A-DE2FAB3456EBQ61668950-697258FD-417D-494C-8511-305889C28795Q70030354-AB33BBDB-4AF3-4C5E-B863-7170C8B4C619Q70299139-1007E5EB-2185-47C6-AC35-068F611FFF41Q70328958-76CD3A46-DDBA-4760-9CD4-9B785BE8A670Q70529847-0DC594DB-E73C-4514-A9B6-DA2A2057CEFDQ70669688-9F5B2575-72C0-48C4-829B-B3B2A01C74D5Q70924512-7D7FB30A-82D1-441A-9DCC-1618C31025D5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
J Jespersen
@ast
J Jespersen
@en
J Jespersen
@es
J Jespersen
@nl
type
label
J Jespersen
@ast
J Jespersen
@en
J Jespersen
@es
J Jespersen
@nl
prefLabel
J Jespersen
@ast
J Jespersen
@en
J Jespersen
@es
J Jespersen
@nl
P106
P31
P496
0000-0002-3059-2356